Flow Cytometry Market to reach USD 11.41 billion by 2032, growing at a CAGR of 8.82%
The Flow Cytometry Market is experiencing significant growth, driven by technological advancements, rising demand for personalized medicine, and the increasing prevalence of chronic diseases such as cancer and autoimmune disorders. For instance, in oncology, flow cytometry has become essential for monitoring immune responses in cancer immunotherapies, such as CAR-T cell treatments. A study published by the National Institutes of Health (NIH) highlights how flow cytometry is used to assess the presence of tumor-specific T cells in patients undergoing immunotherapy. This capability is critical in tracking tumor progression and evaluating the effectiveness of treatments, directly improving patient outcomes.